You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.
Carlsbad, California-based BioSpyder said that HTG has repeatedly and baselessly accused it of infringing HTG's patent for quantitative nuclease protection assay and sequencing improvements.
Natera sued Progenity in June but the firm said its Innatal cell-free DNA noninvasive prenatal test does not infringe any of Natera's six patents.
The suit comes shortly after Progenity filed for an initial public offering in which it is seeking to raise up to $122.6 million.
In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."
The company has added three recently issued patents to the suit, filed Jan. 27, all covering methods for amplifying and sequencing nucleic acids.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.
BioMérieux had alleged infringement of two of its patents associated with nucleotide sequences to detect HIV-1 subtypes.